Blog Tag
4 articles tagged with Readouts. The newest post is from Apr 18, 2026.
Lately CLRB clinical trial data readout, brought stock price per share $2.7 to $3.2, changed 60%+ in one day. https://investor.cellectar.com/news/detail/320/cellectar-biosciences-announces-positive-topline-data-achieving-primary-endpoint-in-pivotal-clinical-study-of-iopofosine-i-131-in-waldenstroms-macroglobulinemia
A secondary endpoint is an additional outcome a clinical trial measures beyond the primary endpoint. It can help support the main finding, add clinical context, or provide more detailed information about the drug’s effect. In biotech, secondary endpoints matter because they help investors understand whether the result is broad, durable, and clinically meaningful.
A primary endpoint is the main outcome a clinical trial is designed to measure. It is the most important endpoint in the study because it is the one the trial is formally powered and analyzed around. In biotech, whether the primary endpoint is met is often the first question investors ask when data is released.
A clinical trial endpoint is the specific outcome a study is designed to measure. In biotech, endpoints are central to how investors, regulators, clinicians, and companies interpret trial data because they define what success actually means. Without a clearly defined endpoint, it is impossible to know whether a trial achieved its goal.
